Blood clots are clumps that occur when blood hardens from a liquid to a solid.
A thrombus or embolus can partly or completely block the flow of blood in a blood vessel.
Clot; Emboli; Thrombi; Thromboembolus; Hypercoagulable state
Situations in which a blood clot is more likely to form in veins include:
Blood clots are also more likely to form after an injury. People with cancer, obesity, and liver or kidney disease are also prone to blood clots.
Smoking also increases the risk of forming blood clots.
Conditions that are passed down through families (inherited) may make you more likely to form abnormal blood clots. Inherited conditions that affect clotting are:
Other rare conditions, such as protein C, protein S, and antithrombin III deficiencies.
A blood clot may block an artery or vein in an organ, affecting the:
Flora Peyvandi practices in Milano, Italy. Peyvandi is rated as an Elite expert by MediFind in the treatment of Blood Clots. She is also highly rated in 44 other conditions, according to our data. Her top areas of expertise are Blood Clots, Hemophilia A, Von Willebrand Disease (VWD), Synovectomy, and Bone Marrow Transplant.
James Bussel is a Pediatrics specialist and a Pediatric Hematologist Oncology expert in New York, New York. Bussel has been practicing medicine for over 48 years and is rated as an Elite expert by MediFind in the treatment of Blood Clots. He is also highly rated in 8 other conditions, according to our data. His top areas of expertise are Immune Thrombocytopenia, Blood Clots, Anemia, Leukemia, and Bone Marrow Transplant. He is licensed to treat patients in New York.
Margaret Ragni is a Hematologist in Pittsburgh, Pennsylvania. Ragni has been practicing medicine for over 48 years and is rated as an Elite expert by MediFind in the treatment of Blood Clots. She is also highly rated in 13 other conditions, according to our data. Her top areas of expertise are Blood Clots, Hemophilia A, Von Willebrand Disease (VWD), Hemophilia B, and Knee Replacement. She is licensed to treat patients in Pennsylvania.
Summary: The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
Summary: This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in participants with mild or moderate hemophilia A without inhibitors against factor VIII (FVIII).
Published Date: April 29, 2022
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Anderson JA, Hogg KE, Weitz JI. Hypercoagulable states. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 140.
Cross SS. Ischaemia, infarction and shock . In: Cross SS, ed. Underwood's Pathology. 7th ed. Philadelphia, PA: Elsevier; 2019:chap 7.
Schafer AI. Approach to the patient with bleeding and thrombosis: hypercoagulable states. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 162.